Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC

Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC

Resistance to the tyrosine kinase inhibitor Sorafenib, which is the standard treatment for advanced hepatocellular carcinoma, is a major clinical challenge. Here, the authors show that phosphoglycerate dehydrogenase, a key enzyme in the serine synthesis pathway, drives sorafenib resistance.

Guardado en:
Detalles Bibliográficos
Autores principales: Lai Wei, Derek Lee, Cheuk-Ting Law, Misty Shuo Zhang, Jialing Shen, Don Wai-Ching Chin, Allen Zhang, Felice Ho-Ching Tsang, Ceci Lok-Sze Wong, Irene Oi-Lin Ng, Carmen Chak-Lui Wong, Chun-Ming Wong
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/1f27ce98d13a42cd9355ac519e4b7c2f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/1f27ce98d13a42cd9355ac519e4b7c2f

Ejemplares similares